The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Apellis Pharmaceuticals Inc’s stock clocked out at $19.26, down -0.05% from its previous closing price of $19.27. In other words, the price has decreased by -$0.05 from its previous closing price. On the day, 1.3 million shares were traded.
Ratios:
To gain a deeper understanding of APLS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 4.08. In the meantime, Its Debt-to-Equity ratio is 2.86 whereas as Long-Term Debt/Eq ratio is at 2.82.
On May 09, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $23.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $44.Cantor Fitzgerald initiated its Overweight rating on April 29, 2025, with a $44 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 12 ’25 when Townsend Adam J. bought 220,961 shares for $17.76 per share.
Chopas James George sold 183 shares of APLS for $4,543 on Mar 17 ’25. The VP/Chief Accounting Officer now owns 47,955 shares after completing the transaction at $24.82 per share. On Mar 17 ’25, another insider, Chopas James George, who serves as the Officer of the company, bought 183 shares for $24.82 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.12 while its Price-to-Book (P/B) ratio in mrq is 14.74.
Stock Price History:
Over the past 52 weeks, APLS has reached a high of $43.76, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is 3.89%, while the 200-Day Moving Average is calculated to be -29.12%.
Shares Statistics:
A total of 125.66M shares are outstanding, with a floating share count of 103.36M. Insiders hold about 17.76% of the company’s shares, while institutions hold 100.11% stake in the company.
Earnings Estimates
As of right now, 12.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.14 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.4 and -$2.38 for the fiscal current year, implying an average EPS of -$1.87. EPS for the following year is -$0.75, with 13.0 analysts recommending between $1.01 and -$1.88.
Revenue Estimates
In the current quarter, 18 analysts expect revenue to total $186.4M. It ranges from a high estimate of $201.84M to a low estimate of $170.36M. As of the current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $199.69MFor the next quarter, 18 analysts are estimating revenue of $201.88M. There is a high estimate of $234.4M for the next quarter, whereas the lowest estimate is $174.77M.
A total of 20 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $822.16M, while the lowest revenue estimate was $716.26M, resulting in an average revenue estimate of $769.07M. In the same quarter a year ago, actual revenue was $781.37MBased on 21 analysts’ estimates, the company’s revenue will be $948.53M in the next fiscal year. The high estimate is $1.21B and the low estimate is $795.66M.
